Home » Drug Information
Recently Approved Drugs
The following database contains a listing of drugs approved by the Food and Drug Administration (FDA) for sale in the United States. The database is searchable by year or by medical area. Drug information typically includes the drug name, approval status, indication of use, and clinical trial results.
Find out more about the types of drugs included in this listing.
Year: [2009] | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | View By Medical Area
Adcirca (tadalafil); Eli Lilly;
For the treatment of pulmonary arterial hypertension, Approved May 2009
Atryn (antithrombin recombinant lyophilized powder for reconstitution); GTC BioTherapeutics;
For the prevention of peri-operative and peri-partum thromboembolic events, Approved January 2009
Cycloset, bromocriptine mesylate; VeroScience;
For the treatment of type 2 diabetes mellitus, Approved May 2009
Atryn (antithrombin recombinant lyophilized powder for reconstitution); GTC BioTherapeutics;
For the prevention of peri-operative and peri-partum thromboembolic events, Approved January 2009
Samsca (tolvaptan); Otsuka;
For the treatment of hyponatremia, Approved May of 2009
Besivance (besifloxacin ophthalmic suspension); Bausch & Lomb;
For the treatment of bacterial conjunctivitis, Approved June 2009
Coartem (artemether/lumefantrine); Novartis;
For the treatment of malaria infections due to Plasmodium falciparum, Approved April 2009
Ixiaro (Japanese Encephalitis Vaccine, Inactivated, Adsorbed); Intercell AG;
For the prevention of disease caused by Japanese encephalitis virus, Approved March 2009
Cimzia (certolizumab pegol); UCB;
For the treatment of rheumatoid arthritis, Approved May of 2009
Savella (milnacipran hydrochloride); Forest Labs;
For the treatment of fibromyalgia, Approved January 2009
Afinitor (everolimus); Novartis;
For the treatment of renal cell carcinoma, Approved March 2009
Gelnique (oxybutynin chloride); Watson Labs;
For the treatment of overactive bladder, Approved January 2009
Cambia (diclofenac potassium for oral solution); Kowa Pharmaceuticals;
For the treatment of migraine attacks, Approved June of 2009
Edluar (zolpidem tartrate); Orexo;
For the treatment of insomnia, Approved March 2009
Zipsor (diclofenac potassium); Xanodyne;
For the treatment of mild to moderate acute pain, Approved June 2009
Afinitor (everolimus); Novartis;
For the treatment of renal cell carcinoma, Approved March 2009
Besivance (besifloxacin ophthalmic suspension); Bausch & Lomb;
For the treatment of bacterial conjunctivitis, Approved June 2009
Ozurdex (dexamethasone); Allergan;
For the treatment of macular edema following branch retinal vein occlusion or central retinal vein occlusion, Approved June 2009
Edluar (zolpidem tartrate); Orexo;
For the treatment of insomnia, Approved March 2009
Fanapt (iloperidone); Vanda;
For the treatment of schizophrenia, Approved May of 2009
Adcirca (tadalafil); Eli Lilly;
For the treatment of pulmonary arterial hypertension, Approved May 2009
Cimzia (certolizumab pegol); UCB;
For the treatment of rheumatoid arthritis, Approved May of 2009
Uloric (febuxostat); Takeda;
For the treatment of chronic hyperuricemia in patients with gout, Approved February 2009
Atryn (antithrombin recombinant lyophilized powder for reconstitution); GTC BioTherapeutics;
For the prevention of peri-operative and peri-partum thromboembolic events, Approved January 2009
